WEBVTT
Kind: captions
Language: en

00:00:04.549 --> 00:00:07.130 

natural<00:00:05.549> tetracyclines<00:00:06.330> are<00:00:06.540> a<00:00:06.569> class<00:00:06.870> of

00:00:07.130 --> 00:00:07.140 
natural tetracyclines are a class of

00:00:07.140 --> 00:00:09.290 
natural tetracyclines are a class of
antibiotics<00:00:07.430> comprised<00:00:08.430> of<00:00:08.670> a<00:00:08.790> distinct

00:00:09.290 --> 00:00:09.300 
antibiotics comprised of a distinct

00:00:09.300 --> 00:00:11.560 
antibiotics comprised of a distinct
family<00:00:09.690> of<00:00:09.840> substituted<00:00:10.590> hydro<00:00:10.889> naphthalene

00:00:11.560 --> 00:00:11.570 
family of substituted hydro naphthalene

00:00:11.570 --> 00:00:15.020 
family of substituted hydro naphthalene
for<00:00:12.570> fused<00:00:13.110> six-membered<00:00:14.070> rings<00:00:14.370> form<00:00:14.820> the

00:00:15.020 --> 00:00:15.030 
for fused six-membered rings form the

00:00:15.030 --> 00:00:16.790 
for fused six-membered rings form the
basic<00:00:15.389> structure<00:00:15.809> from<00:00:15.990> which<00:00:16.080> the<00:00:16.410> various

00:00:16.790 --> 00:00:16.800 
basic structure from which the various

00:00:16.800 --> 00:00:20.060 
basic structure from which the various
tetracyclines<00:00:17.580> are<00:00:17.790> made<00:00:18.110> all<00:00:19.110> tetracyclines

00:00:20.060 --> 00:00:20.070 
tetracyclines are made all tetracyclines

00:00:20.070 --> 00:00:21.890 
tetracyclines are made all tetracyclines
approved<00:00:20.520> for<00:00:20.820> humans<00:00:21.210> including

00:00:21.890 --> 00:00:21.900 
approved for humans including

00:00:21.900 --> 00:00:24.290 
approved for humans including
tetracycline<00:00:22.620> itself<00:00:23.010> are<00:00:23.300> fermentation

00:00:24.290 --> 00:00:24.300 
tetracycline itself are fermentation

00:00:24.300 --> 00:00:26.000 
tetracycline itself are fermentation
products<00:00:24.810> or<00:00:24.960> are<00:00:25.320> derived<00:00:25.770> from

00:00:26.000 --> 00:00:26.010 
products or are derived from

00:00:26.010 --> 00:00:28.520 
products or are derived from
fermentation<00:00:26.910> products<00:00:27.390> by<00:00:27.540> semi<00:00:27.990> synthesis

00:00:28.520 --> 00:00:28.530 
fermentation products by semi synthesis

00:00:28.530 --> 00:00:31.299 
fermentation products by semi synthesis
this<00:00:29.310> also<00:00:29.580> includes<00:00:30.180> doxycycline

00:00:31.299 --> 00:00:31.309 
this also includes doxycycline

00:00:31.309 --> 00:00:35.660 
this also includes doxycycline
minocycline<00:00:32.309> and<00:00:33.680> recently<00:00:34.680> approved<00:00:35.070> taiga

00:00:35.660 --> 00:00:35.670 
minocycline and recently approved taiga

00:00:35.670 --> 00:00:41.030 
minocycline and recently approved taiga
cycling<00:00:38.660> the<00:00:39.660> difficulty<00:00:40.260> to<00:00:40.410> functionalize

00:00:41.030 --> 00:00:41.040 
cycling the difficulty to functionalize

00:00:41.040 --> 00:00:43.160 
cycling the difficulty to functionalize
the<00:00:41.310> sensitive<00:00:41.790> tetracyclic<00:00:42.570> core<00:00:42.870> has

00:00:43.160 --> 00:00:43.170 
the sensitive tetracyclic core has

00:00:43.170 --> 00:00:44.900 
the sensitive tetracyclic core has
resulted<00:00:43.470> in<00:00:43.740> limited<00:00:44.190> chemical<00:00:44.640> diversity

00:00:44.900 --> 00:00:44.910 
resulted in limited chemical diversity

00:00:44.910 --> 00:00:47.330 
resulted in limited chemical diversity
of<00:00:45.300> the<00:00:45.420> class<00:00:45.660> and<00:00:46.020> slowed<00:00:46.620> down<00:00:46.890> the<00:00:47.100> pace<00:00:47.310> of

00:00:47.330 --> 00:00:47.340 
of the class and slowed down the pace of

00:00:47.340 --> 00:00:52.040 
of the class and slowed down the pace of
discovery<00:00:47.670> in<00:00:48.300> the<00:00:48.450> area<00:00:50.240> this<00:00:51.240> remained<00:00:51.690> true

00:00:52.040 --> 00:00:52.050 
discovery in the area this remained true

00:00:52.050 --> 00:00:55.010 
discovery in the area this remained true
until<00:00:52.440> 2005<00:00:53.280> when<00:00:53.670> a<00:00:53.850> practical<00:00:54.480> synthetic

00:00:55.010 --> 00:00:55.020 
until 2005 when a practical synthetic

00:00:55.020 --> 00:00:56.900 
until 2005 when a practical synthetic
route<00:00:55.290> to<00:00:55.500> this<00:00:55.650> complex<00:00:56.280> class<00:00:56.640> of

00:00:56.900 --> 00:00:56.910 
route to this complex class of

00:00:56.910 --> 00:00:59.240 
route to this complex class of
antibiotics<00:00:57.690> was<00:00:58.140> discovered<00:00:58.680> and<00:00:58.829> published

00:00:59.240 --> 00:00:59.250 
antibiotics was discovered and published

00:00:59.250 --> 00:01:01.340 
antibiotics was discovered and published
by<00:00:59.340> researchers<00:01:00.090> at<00:01:00.300> Harvard<00:01:00.690> University

00:01:01.340 --> 00:01:01.350 
by researchers at Harvard University

00:01:01.350 --> 00:01:03.650 
by researchers at Harvard University
allowing<00:01:02.160> synthesis<00:01:02.700> of<00:01:02.850> an<00:01:02.970> unprecedented

00:01:03.650 --> 00:01:03.660 
allowing synthesis of an unprecedented

00:01:03.660 --> 00:01:06.110 
allowing synthesis of an unprecedented
series<00:01:04.079> of<00:01:04.259> structurally<00:01:05.100> diverse<00:01:05.519> analogues

00:01:06.110 --> 00:01:06.120 
series of structurally diverse analogues

00:01:06.120 --> 00:01:10.010 
series of structurally diverse analogues
of<00:01:06.330> tetracycline<00:01:08.810> tetra<00:01:09.810> phase

00:01:10.010 --> 00:01:10.020 
of tetracycline tetra phase

00:01:10.020 --> 00:01:12.230 
of tetracycline tetra phase
pharmaceuticals<00:01:10.860> has<00:01:11.040> expanded<00:01:11.670> the<00:01:11.820> basic

00:01:12.230 --> 00:01:12.240 
pharmaceuticals has expanded the basic

00:01:12.240 --> 00:01:14.330 
pharmaceuticals has expanded the basic
research<00:01:12.570> into<00:01:12.990> a<00:01:13.020> platform<00:01:13.650> that<00:01:13.860> delivers

00:01:14.330 --> 00:01:14.340 
research into a platform that delivers

00:01:14.340 --> 00:01:16.430 
research into a platform that delivers
previously<00:01:15.000> inaccessible<00:01:15.270> analogues<00:01:16.229> that

00:01:16.430 --> 00:01:16.440 
previously inaccessible analogues that

00:01:16.440 --> 00:01:18.620 
previously inaccessible analogues that
are<00:01:16.680> efficiently<00:01:17.190> produced<00:01:17.760> and<00:01:18.030> have<00:01:18.450> unique

00:01:18.620 --> 00:01:18.630 
are efficiently produced and have unique

00:01:18.630 --> 00:01:21.330 
are efficiently produced and have unique
properties

00:01:21.330 --> 00:01:21.340 

00:01:21.340 --> 00:01:24.279 

the<00:01:22.340> novel<00:01:22.759> analogues<00:01:23.270> are<00:01:23.479> prepared<00:01:23.929> by<00:01:24.170> an

00:01:24.279 --> 00:01:24.289 
the novel analogues are prepared by an

00:01:24.289 --> 00:01:26.529 
the novel analogues are prepared by an
efficient<00:01:24.770> convergent<00:01:25.369> approach<00:01:25.729> including

00:01:26.529 --> 00:01:26.539 
efficient convergent approach including

00:01:26.539 --> 00:01:28.599 
efficient convergent approach including
a<00:01:26.689> single<00:01:27.049> step<00:01:27.259> reaction<00:01:27.289> between<00:01:28.009> a<00:01:28.219> d-ring

00:01:28.599 --> 00:01:28.609 
a single step reaction between a d-ring

00:01:28.609 --> 00:01:31.809 
a single step reaction between a d-ring
precursor<00:01:29.479> the<00:01:29.780> left-hand<00:01:30.259> side<00:01:30.560> and<00:01:30.829> an<00:01:31.399> a/b

00:01:31.809 --> 00:01:31.819 
precursor the left-hand side and an a/b

00:01:31.819 --> 00:01:41.670 
precursor the left-hand side and an a/b
precursor<00:01:32.479> the<00:01:32.780> key<00:01:33.049> known

00:01:41.670 --> 00:01:41.680 

00:01:41.680 --> 00:01:44.980 

in<00:01:42.680> that<00:01:42.950> single<00:01:43.400> step<00:01:43.760> the<00:01:44.240> C<00:01:44.570> ring<00:01:44.780> is

00:01:44.980 --> 00:01:44.990 
in that single step the C ring is

00:01:44.990 --> 00:01:47.200 
in that single step the C ring is
constructed<00:01:45.590> setting<00:01:46.010> up<00:01:46.160> the<00:01:46.370> ABCD

00:01:47.200 --> 00:01:47.210 
constructed setting up the ABCD

00:01:47.210 --> 00:01:49.450 
constructed setting up the ABCD
tetracyclic<00:01:48.080> core<00:01:48.410> of<00:01:48.590> the<00:01:48.740> molecule<00:01:49.220> and

00:01:49.450 --> 00:01:49.460 
tetracyclic core of the molecule and

00:01:49.460 --> 00:01:51.790 
tetracyclic core of the molecule and
establishing<00:01:50.240> the<00:01:50.390> desired<00:01:50.810> absolute<00:01:51.560> and

00:01:51.790 --> 00:01:51.800 
establishing the desired absolute and

00:01:51.800 --> 00:01:54.190 
establishing the desired absolute and
relative<00:01:52.090> configuration<00:01:53.090> of<00:01:53.210> every<00:01:53.630> chiral

00:01:54.190 --> 00:01:54.200 
relative configuration of every chiral

00:01:54.200 --> 00:01:56.710 
relative configuration of every chiral
Center<00:01:54.590> present<00:01:55.370> in<00:01:55.490> the<00:01:55.580> final<00:01:55.820> tetracycline

00:01:56.710 --> 00:01:56.720 
Center present in the final tetracycline

00:01:56.720 --> 00:01:59.800 
Center present in the final tetracycline
analogue<00:01:57.260> a<00:01:57.670> wide<00:01:58.670> range<00:01:59.060> of<00:01:59.240> structural

00:01:59.800 --> 00:01:59.810 
analogue a wide range of structural

00:01:59.810 --> 00:02:01.810 
analogue a wide range of structural
variations<00:02:00.440> can<00:02:00.650> be<00:02:00.830> built<00:02:01.070> into<00:02:01.370> the<00:02:01.460> key

00:02:01.810 --> 00:02:01.820 
variations can be built into the key

00:02:01.820 --> 00:02:04.420 
variations can be built into the key
known<00:02:02.270> and<00:02:02.570> left<00:02:02.810> hand<00:02:03.050> side<00:02:03.320> which<00:02:03.920> leads<00:02:04.280> to

00:02:04.420 --> 00:02:04.430 
known and left hand side which leads to

00:02:04.430 --> 00:02:06.490 
known and left hand side which leads to
new<00:02:04.790> tetracycline<00:02:05.630> analogues<00:02:06.170> with

00:02:06.490 --> 00:02:06.500 
new tetracycline analogues with

00:02:06.500 --> 00:02:11.080 
new tetracycline analogues with
unparalleled<00:02:07.010> structural<00:02:07.910> diversity<00:02:10.090> the

00:02:11.080 --> 00:02:11.090 
unparalleled structural diversity the

00:02:11.090 --> 00:02:14.020 
unparalleled structural diversity the
new<00:02:11.300> tetracycline<00:02:12.140> analogues<00:02:12.710> bind<00:02:13.220> the<00:02:13.490> 30s

00:02:14.020 --> 00:02:14.030 
new tetracycline analogues bind the 30s

00:02:14.030 --> 00:02:16.510 
new tetracycline analogues bind the 30s
subunit<00:02:14.330> of<00:02:14.780> the<00:02:14.840> bacterial<00:02:15.530> ribosome<00:02:15.980> at<00:02:16.459> a

00:02:16.510 --> 00:02:16.520 
subunit of the bacterial ribosome at a

00:02:16.520 --> 00:02:19.150 
subunit of the bacterial ribosome at a
site<00:02:16.880> that<00:02:16.910> overlaps<00:02:17.720> the<00:02:18.020> anticodon<00:02:18.620> stem

00:02:19.150 --> 00:02:19.160 
site that overlaps the anticodon stem

00:02:19.160 --> 00:02:25.390 
site that overlaps the anticodon stem
loop<00:02:19.430> of<00:02:19.670> an<00:02:20.030> amino<00:02:20.480> acyl<00:02:20.510> tRNA

00:02:25.390 --> 00:02:25.400 

00:02:25.400 --> 00:02:28.009 

by<00:02:26.400> preventing<00:02:26.940> stable<00:02:27.390> binding<00:02:27.810> of<00:02:27.930> the

00:02:28.009 --> 00:02:28.019 
by preventing stable binding of the

00:02:28.019 --> 00:02:30.290 
by preventing stable binding of the
incoming<00:02:28.500> amino<00:02:28.950> acid<00:02:29.370> at<00:02:29.489> the<00:02:29.610> acceptor<00:02:30.090> site

00:02:30.290 --> 00:02:30.300 
incoming amino acid at the acceptor site

00:02:30.300 --> 00:02:32.839 
incoming amino acid at the acceptor site
the<00:02:30.750> tetracyclines<00:02:31.560> inhibit<00:02:32.129> the<00:02:32.250> elongation

00:02:32.839 --> 00:02:32.849 
the tetracyclines inhibit the elongation

00:02:32.849 --> 00:02:40.260 
the tetracyclines inhibit the elongation
stage<00:02:33.300> of<00:02:33.569> protein<00:02:34.019> synthesis

00:02:40.260 --> 00:02:40.270 

00:02:40.270 --> 00:02:42.820 

tetra<00:02:41.270> phases<00:02:41.630> total<00:02:42.020> synthetic<00:02:42.560> approach

00:02:42.820 --> 00:02:42.830 
tetra phases total synthetic approach

00:02:42.830 --> 00:02:44.890 
tetra phases total synthetic approach
dramatically<00:02:43.640> increases<00:02:44.239> the<00:02:44.270> scope<00:02:44.720> of

00:02:44.890 --> 00:02:44.900 
dramatically increases the scope of

00:02:44.900 --> 00:02:46.600 
dramatically increases the scope of
accessible<00:02:45.500> chemical<00:02:45.980> diversity<00:02:46.489> of

00:02:46.600 --> 00:02:46.610 
accessible chemical diversity of

00:02:46.610 --> 00:02:47.559 
accessible chemical diversity of
tetracyclines

00:02:47.559 --> 00:02:47.569 
tetracyclines

00:02:47.569 --> 00:02:50.260 
tetracyclines
due<00:02:48.530> to<00:02:48.739> the<00:02:48.890> total<00:02:49.099> synthetic<00:02:49.730> nature<00:02:50.060> of<00:02:50.180> the

00:02:50.260 --> 00:02:50.270 
due to the total synthetic nature of the

00:02:50.270 --> 00:02:52.089 
due to the total synthetic nature of the
approach<00:02:50.630> it<00:02:50.930> allows<00:02:51.440> one<00:02:51.709> who<00:02:51.920> not<00:02:52.069> only

00:02:52.089 --> 00:02:52.099 
approach it allows one who not only

00:02:52.099 --> 00:02:54.250 
approach it allows one who not only
modify<00:02:52.940> almost<00:02:53.330> any<00:02:53.510> position<00:02:53.720> on<00:02:54.170> the

00:02:54.250 --> 00:02:54.260 
modify almost any position on the

00:02:54.260 --> 00:02:57.160 
modify almost any position on the
molecule<00:02:54.610> but<00:02:55.610> also<00:02:55.850> to<00:02:56.060> fuse<00:02:56.540> additional

00:02:57.160 --> 00:02:57.170 
molecule but also to fuse additional

00:02:57.170 --> 00:02:59.710 
molecule but also to fuse additional
rings<00:02:57.410> to<00:02:57.650> the<00:02:57.770> tetracyclic<00:02:58.520> core<00:02:58.850> to<00:02:59.390> form

00:02:59.710 --> 00:02:59.720 
rings to the tetracyclic core to form

00:02:59.720 --> 00:03:01.809 
rings to the tetracyclic core to form
completely<00:03:00.350> novel<00:03:00.620> heterocyclic<00:03:01.400> and

00:03:01.809 --> 00:03:01.819 
completely novel heterocyclic and

00:03:01.819 --> 00:03:04.270 
completely novel heterocyclic and
polycyclic<00:03:02.420> tetracycline<00:03:03.410> analogs

00:03:04.270 --> 00:03:04.280 
polycyclic tetracycline analogs

00:03:04.280 --> 00:03:06.430 
polycyclic tetracycline analogs
although<00:03:05.150> these<00:03:05.360> synthetic<00:03:05.959> products

00:03:06.430 --> 00:03:06.440 
although these synthetic products

00:03:06.440 --> 00:03:08.350 
although these synthetic products
contain<00:03:06.800> novel<00:03:07.190> modifications<00:03:08.000> they

00:03:08.350 --> 00:03:08.360 
contain novel modifications they

00:03:08.360 --> 00:03:10.420 
contain novel modifications they
typically<00:03:08.780> retain<00:03:09.350> and<00:03:09.680> in<00:03:09.920> many<00:03:10.130> cases

00:03:10.420 --> 00:03:10.430 
typically retain and in many cases

00:03:10.430 --> 00:03:12.910 
typically retain and in many cases
improve<00:03:11.180> antibiotic<00:03:11.510> activity<00:03:12.290> and

00:03:12.910 --> 00:03:12.920 
improve antibiotic activity and

00:03:12.920 --> 00:03:15.130 
improve antibiotic activity and
frequently<00:03:13.670> overcome<00:03:14.330> tetracycline

00:03:15.130 --> 00:03:15.140 
frequently overcome tetracycline

00:03:15.140 --> 00:03:17.470 
frequently overcome tetracycline
resistance<00:03:15.340> mediated<00:03:16.340> by<00:03:16.489> a<00:03:16.519> flux<00:03:17.060> or

00:03:17.470 --> 00:03:17.480 
resistance mediated by a flux or

00:03:17.480 --> 00:03:21.820 
resistance mediated by a flux or
ribosome<00:03:18.200> protection<00:03:18.799> mechanisms<00:03:20.830> with

00:03:21.820 --> 00:03:21.830 
ribosome protection mechanisms with

00:03:21.830 --> 00:03:23.770 
ribosome protection mechanisms with
thousands<00:03:22.370> of<00:03:22.430> analogs<00:03:22.880> produced<00:03:23.360> and<00:03:23.630> with

00:03:23.770 --> 00:03:23.780 
thousands of analogs produced and with

00:03:23.780 --> 00:03:25.990 
thousands of analogs produced and with
clinical<00:03:24.230> trials<00:03:24.260> underway<00:03:25.100> the<00:03:25.489> tetra<00:03:25.819> phase

00:03:25.990 --> 00:03:26.000 
clinical trials underway the tetra phase

00:03:26.000 --> 00:03:27.940 
clinical trials underway the tetra phase
platform<00:03:26.600> has<00:03:26.810> already<00:03:27.170> demonstrated<00:03:27.410> that

00:03:27.940 --> 00:03:27.950 
platform has already demonstrated that

00:03:27.950 --> 00:03:29.770 
platform has already demonstrated that
it<00:03:28.220> is<00:03:28.250> a<00:03:28.370> powerful<00:03:28.970> engine<00:03:29.209> for<00:03:29.450> the

00:03:29.770 --> 00:03:29.780 
it is a powerful engine for the

00:03:29.780 --> 00:03:31.900 
it is a powerful engine for the
discovery<00:03:30.350> as<00:03:30.620> well<00:03:30.950> as<00:03:31.130> for<00:03:31.340> the<00:03:31.400> development

00:03:31.900 --> 00:03:31.910 
discovery as well as for the development

00:03:31.910 --> 00:04:02.140 
discovery as well as for the development
of<00:03:32.090> new<00:03:32.200> tetracycline<00:03:33.200> antibiotics

00:04:02.140 --> 00:04:02.150 

00:04:02.150 --> 00:04:04.239 

you

